FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569085293> ?p ?o ?g. }

• W1569085293 startingPage "559" @default.
• W1569085293 abstract "Vaccines have contributed more to public health in this country and around the world than any other medical product, device, or procedure.(1)Vaccines have effectively controlled or eradicated the once fatal and debilitating diseases of smallpox, diphtheria, tetanus, pertussis, measles, mumps, rubella, and polio.(2) Yet, the imposition of strict product liability for adverse side-effects suffered by some users substantially deterred the development and manufacture of these vaccines and continues to hinder future access to them.(3) In the 1970s and early 1980s, twelve of the sixteen American manufacturers simply dropped out of the market, seriously threatening supply.(4) In response, Congress enacted legislation to address the detrimental effect the tort liability system was having on innovation and access.(5) In order to avoid repeating history, we must learn from these past scenarios and attempt to structure an effective method to deal with the problems conventional tort liability places in the path of finding an answer to the Acquired Immunodeficiency Syndrome (AIDS) epidemic.(6)AIDS is deemed the worst infectious disease in history.(7) The human immunodeficiency virus (HIV), responsible for transmitting AIDS, strikes all sectors of society, regardless of racial, economic, sexual, and age boundaries.(8) Fortunately, private industry has the ability to formulate, produce, and test an vaccine.(9) As of 1990, the National Institute of Allergic and Infectious Diseases reported at least thirty vaccines under development world-wide,(10) seven of which have already reached the human testing stage.(11) However, if the tort liability problems persist, these potential vaccines may never reach the market. Federal legislation is the necessary solution to the detrimental effect that imposition of traditional tort liability has on the development, marketing, and price of an vaccine.(12)I. GENERAL BACKGROUNDThe term AIDS designates the specific group of diseases and conditions that are indicative of the severe immunosuppression resulting from infection with HIV.(13) By August 1991 the total number of cases in the United States reached 186,895.(14) Some 1,500,000 United States citizens are infected with the HIV virus, and estimates predict that 365,000 Americans will develop by the end of 1992.(15) The world-wide picture is dimmer yet, with approximately eight to ten million people infected.(16) The most distressing statistic is the high mortality rate.(17) The average patient lives only eighteen months after diagnosis, and more than eighty-five percent die within three years.(18) is now the leading cause of death in New York City among young to middle-age men and women.(19) Currently there is no known cure for AIDS, and all scientific evidence indicates that individuals testing positive for the virus will eventually contract and die.(20) The above statistics indicate that is a frightening contagion that will challenge our medical, scientific, and legal communities for years to come.(21) Not surprisingly, health officials have propelled to the top of biomedical and public health agendas.(22)II. VACCINATION AS THE PREFERABLE MEDICAL APPROACHPractitioners can use various medical approaches, including drug therapy and vaccination, to combat AIDS.(23) In 1991 the Pharmaceutical Manufacturers Association identified fourteen approved drugs, as well as eighty-eight drugs and vaccines in development for and AIDS-related conditions.(24) The major goal of existing drug therapies is to increase the quantity and quality Of life: in other words, to delay mortality and to reduce morbidity.(25) While prolonging life and easing pain are important, a preventive or curative approach is clearly preferable and, thus, development of an is a highly desirable goal.(26)A vaccine is a biological agent derived from a living organism, as compared to chemically derived drugs, used for human immunization against a virus. …" @default.
• W1569085293 created "2016-06-24" @default.
• W1569085293 creator A5085343056 @default.
• W1569085293 date "1992-04-01" @default.
• W1569085293 modified "2023-09-26" @default.
• W1569085293 title "Aids Vaccine Manufacturers V. Tort Regime:The Need For Alternatives" @default.
• W1569085293 hasPublicationYear "1992" @default.
• W1569085293 type Work @default.
• W1569085293 sameAs 1569085293 @default.
• W1569085293 citedByCount "0" @default.
• W1569085293 crossrefType "journal-article" @default.
• W1569085293 hasAuthorship W1569085293A5085343056 @default.
• W1569085293 hasConcept C144133560 @default.
• W1569085293 hasConcept C159047783 @default.
• W1569085293 hasConcept C162324750 @default.
• W1569085293 hasConcept C17744445 @default.
• W1569085293 hasConcept C199539241 @default.
• W1569085293 hasConcept C200635333 @default.
• W1569085293 hasConcept C22070199 @default.
• W1569085293 hasConcept C2776438120 @default.
• W1569085293 hasConcept C2777351106 @default.
• W1569085293 hasConcept C2777834853 @default.
• W1569085293 hasConcept C2778417375 @default.
• W1569085293 hasConcept C2778814567 @default.
• W1569085293 hasConcept C4870876 @default.
• W1569085293 hasConcept C50522688 @default.
• W1569085293 hasConcept C71924100 @default.
• W1569085293 hasConceptScore W1569085293C144133560 @default.
• W1569085293 hasConceptScore W1569085293C159047783 @default.
• W1569085293 hasConceptScore W1569085293C162324750 @default.
• W1569085293 hasConceptScore W1569085293C17744445 @default.
• W1569085293 hasConceptScore W1569085293C199539241 @default.
• W1569085293 hasConceptScore W1569085293C200635333 @default.
• W1569085293 hasConceptScore W1569085293C22070199 @default.
• W1569085293 hasConceptScore W1569085293C2776438120 @default.
• W1569085293 hasConceptScore W1569085293C2777351106 @default.
• W1569085293 hasConceptScore W1569085293C2777834853 @default.
• W1569085293 hasConceptScore W1569085293C2778417375 @default.
• W1569085293 hasConceptScore W1569085293C2778814567 @default.
• W1569085293 hasConceptScore W1569085293C4870876 @default.
• W1569085293 hasConceptScore W1569085293C50522688 @default.
• W1569085293 hasConceptScore W1569085293C71924100 @default.
• W1569085293 hasIssue "2" @default.
• W1569085293 hasLocation W15690852931 @default.
• W1569085293 hasOpenAccess W1569085293 @default.
• W1569085293 hasPrimaryLocation W15690852931 @default.
• W1569085293 hasRelatedWork W1250374636 @default.
• W1569085293 hasRelatedWork W1505088718 @default.
• W1569085293 hasRelatedWork W151313890 @default.
• W1569085293 hasRelatedWork W1821758441 @default.
• W1569085293 hasRelatedWork W1980491621 @default.
• W1569085293 hasRelatedWork W1992008286 @default.
• W1569085293 hasRelatedWork W2094754076 @default.
• W1569085293 hasRelatedWork W2119787561 @default.
• W1569085293 hasRelatedWork W2171834980 @default.
• W1569085293 hasRelatedWork W2202385283 @default.
• W1569085293 hasRelatedWork W2264448324 @default.
• W1569085293 hasRelatedWork W2287071778 @default.
• W1569085293 hasRelatedWork W2303390777 @default.
• W1569085293 hasRelatedWork W2325205506 @default.
• W1569085293 hasRelatedWork W2470873549 @default.
• W1569085293 hasRelatedWork W32827828 @default.
• W1569085293 hasRelatedWork W182464600 @default.
• W1569085293 hasRelatedWork W2274305890 @default.
• W1569085293 hasRelatedWork W2293016693 @default.
• W1569085293 hasRelatedWork W2296288747 @default.
• W1569085293 hasVolume "49" @default.
• W1569085293 isParatext "false" @default.
• W1569085293 isRetracted "false" @default.
• W1569085293 magId "1569085293" @default.
• W1569085293 workType "article" @default.